BRIEF-Biontech And Bristol Myers Squibb Report Encouraging Global Phase 2 Data For Pumitamig In Advanced Nsclc After Progression On Immunotherapy Plus Chemotherapy

1

Oct 25 (Reuters) – BioNTech SE: * BIONTECH AND BRISTOL MYERS SQUIBB REPORT ENCOURAGING GLOBAL PHASE 2 DATA FOR PUMITAMIG IN ADVANCED NSCLC AFTER PROGRESSION ON IMMUNOTHERAPY PLUS CHEMOTHERAPY Source

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)